Adam Berger is an Ophthalmology physician. OpenAlex indexes 22 publications with 1,344 citations (h-index 14); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
250 Avenue K SW
Suite 200
Winter Haven, FL 338803919
Telephone
863-297-5400Provider last certified this registry record 4 Jun 2025.
Clinical trials
- Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin
Sponsor: Rutgers, The State University of New Jersey
Overall officialPhase 1TerminatedNCT04163952 - Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Sponsor: Rutgers, The State University of New Jersey
Overall officialPhase 2TerminatedNCT02748564
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- OnMark, Inc.Program year202511 payments
- Alcon Research LLCProgram year20251 payment
- Astellas Pharma US IncProgram year202510 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
87%Antineovascularisation agents77.4%Faricimab-svoa100%Vabysmo0%Part D + Part B<11 patientsComplement Inhibitor7.6%Avacincaptad pegol99%Izervay1%Part D + Part B≥43 patients+ 6 more classes in this area
Cancer & immunology
12.7%Complement Inhibitor10%Pegcetacoplan99%Syfovre1%Part D + Part B<11 patientsVascular Endothelial Growth Factor Inhibitor2.7%Aflibercept89%Eylea11%Part D + Part B≥156 patientsDermatology
0.1%Corticosteroid0.1%Triamcinolone acetonide100%Part B, office-administered≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intravitreal aflibercept 8 mg in patients from Japan with diabetic macular edema: 48-week subgroup analysis of the PHOTON trial
Japanese Journal of Ophthalmology
2025 - Aflibercept Biosimilar MYL-1701P vs Reference Aflibercept in Diabetic Macular Edema
JAMA Ophthalmology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”